Subtherapeutic triazole concentrations as result of a drug-drug interaction with lumacaftor/ivacaftor

T.J.L. Smeets, H. van der Sijs, H.M. Janssens, E.J. Ruijgrok,B.C.M. de Winter

Journal of Cystic Fibrosis（2024）

引用 0|浏览2

暂无评分

摘要

•Strong induction of CYP3A4 and UGT by lumacaftor/ivacaftor (Orkambi®, LUM/IVA) can reduce the plasma concentration of triazole antifungals.•Concomitant use of LUM/IVA with itraconazole, posaconazole or voriconazole resulted in subtherapeutic triazole levels in 76% of the samples in adults and children.•Higher doses of triazoles are needed in CF patients treated with LUM/IVA to reach target concentrations.

查看译文

关键词

Cystic fibrosis,Triazoles,Lumacaftor/ivacaftor,Drug-drug interaction

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要